FDA Approves Drospirenone Tablet for Pregnancy Prevention


A progestin-only pill, this estrogen-free oral contraceptive is intended as a 24 active and 4 inactive tablet dosing regimen.

Officials with the FDA have approved Exeltis’ drospirenone 4 mg (Slynd) oral tablet for pregnancy prevention, according to the company.

A progestin-only pill, this estrogen-free oral contraceptive is intended as a 24 active and 4 inactive tablet dosing regimen. The regimen also allows a 24-hour missed tablet window.

According to Exeltis, a division of Insud Pharma, this contraceptive tablet could be made available by Fall 2019.

Drospirenone is a synthetic form of progesterone that has a similar pharmacological profile to the natural hormone progesterone. In clinical trials, drospirenone showed no instances of thromboembolic events experienced by some women taking combined oral contraceptives (COCs), which by definition contain estrogen.

In addition, the approval of Exeltis’ New Drug Application for drospirenone does not include a black box warning, unlike other COCs, according to the company. However, for females with conditions that predispose to hyperkalemia, drospirenone is contraindicated due to its anti-mineralocorticoid activity.

"This safety profile was demonstrated for all patients, including higher-risk populations like smokers, older women, and subjects with a Body Mass Index (BMI) >30," said Enrico Colli, MD, Chief Scientific Officer, in a prepared statement.

According to Salustiano Perez, President of Exeltis USA, Inc. drospirenone may be an excellent choice for women who need or want safe and effective oral contraception without the risks of estrogen, including breastfeeding mothers.

Contraindications for drospirenone include renal impairment, adrenal insufficiency, presence or history of progestin sensitive cancers, liver tumors, benign or malignant, or hepatic impairment, or undiagnosed abnormal uterine bleeding.


Exeltis USA, Inc. Announces the Approval of Slynd™, the First and Only Progestin-Only Pill Providing Pregnancy Prevention with a 24/4 Dosing Regimen and 24-hour Missed Pill Window [news release]. Florham Park, NJ; June 6, 2019: Exeltis. https://www.prnewswire.com/news-releases/exeltis-usa-inc-announces-the-approval-of-slynd-the-first-and-only-progestin-only-pill-providing-pregnancy-prevention-with-a-244-dosing-regimen-and-24-hour-missed-pill-window-300863390.html. Accessed June 7, 2019.

Related Videos
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
cropped view of man performing chest compression on dummy during cpr training class - Image credit: LIGHTFIELD STUDIOS | stock.adobe.com
Medicine law concept. Judges gavel with pills | Image Credit: Iren Moroz - stock.adobe.com
Image credit: New Africa | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image Credit: Pixel-Shot | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.